Filter posts

Fireside Chat: James Noble Says Go for IPO

“Go for it,” was the parting advice James Noble, CEO and co-founder of Adaptimmune, had …

Politicking Biopharma Delays Cures

Forbes’ Matthew Herper ran a guest post from Robert Nelsen, cofounder and managing director of …

PTAB Ruling Proves Medical Innovation Under Attack

There’s more evidence today that the IPR system needs to be fixed. PTAB ruled on …

BIO on CNBC: IPR System Weakens Medical Innovation

Last night Ron Cohen, M.D., CEO of Acorda Therapeutics and BIO’s board chair, appeared on …

Here are the Facts about the IPR Kill Rate

FiercePhrma recently ran an article repeating a dubious analysis of the crisis caused by the …

102 Organizations Urge Congress to Maintain a Strong Patent System and Protect Innovation

A diverse group of more than 100 national and state-based advocacy organizations have united to …

Seventy Nine House Members Express Concern with H.R. 9

House leaders made the decision earlier this month to remove patent reform legislation from the …

CNBC Commentary: Hedge funds, 'reverse trolls' crushing biopharma innovation

Patents are the lifeblood of medical innovation. They are the cornerstone that enables companies to …

BIO 2015 Provides Local Shoe Shiner with School Supplies for Kids in Need

For the past decade, William Green, a center city shoe shiner, hosts a Children’s Cookout …

Scientific American WorldView Super Session and the Future of Innovation

The final Super Session of the 2015 BIO International Convention today featured a panel of …